At the time of writing, Trevi Therapeutics Inc [TRVI] stock is trading at $6.58, up 10.59%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TRVI shares have gain 5.11% over the last week, with a monthly amount drifted -4.64%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Trevi Therapeutics Inc [NASDAQ: TRVI] stock has seen the most recent analyst activity on May 28, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $21. Previously, Raymond James upgraded its rating to Strong Buy on March 10, 2025, and elevated its price target to $29. On March 10, 2025, Needham reiterated its Buy rating and revised its price target to $25 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $7.50 on December 12, 2024. Raymond James started tracking with a Outperform rating for this stock on August 30, 2024, and assigned it a price target of $9. In a note dated August 30, 2024, H.C. Wainwright initiated an Buy rating and provided a target price of $6 on this stock.
For the past year, the stock price of Trevi Therapeutics Inc fluctuated between $2.30 and $7.48. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Trevi Therapeutics Inc [NASDAQ: TRVI] shares were valued at $6.58 at the most recent close of the market. An investor can expect a potential return of 21.58% based on the average TRVI price forecast.
Analyzing the TRVI fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.58 and Total Capital is -0.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Trevi Therapeutics Inc [NASDAQ:TRVI] has a current ratio of 15.38. Further, the Quick Ratio stands at 15.38, while the Cash Ratio is 2.82.
Transactions by insiders
Recent insider trading involved SCIASCIA THOMAS, Chief Scientific Officer, that happened on Mar 25 ’25 when 2631.0 shares were sold. President & CEO, GOOD JENNIFER L completed a deal on Mar 21 ’25 to sell 5263.0 shares. Meanwhile, Officer GOOD JENNIFER L bought 5263.0 shares on Mar 21 ’25.
